Health Business Blog � Blog Archive � Singapore’s biomedical strategy: "Kevin Tan, Assistant Head of the Pharmaceuticals & Biotechnology Sciences group with Singapore’s Economic Development Board spoke Monday about Singapore’s biomedical strategy and the interrelationship between health care delivery and research. The country’s overall strategy to be a biomedical hub strengthens its position as a medical travel destination, especially for complex procedures and treatments.
Singapore is pursuing a holistic strategy comprising small molecule pharmaceuticals, biotech drugs and biotechnology, medical devices, and services, and spanning the value chain from discovery through manufacturing. The country has attracted scores of well-known international companies in each of the sectors. Large pharma companies including GSK, Lilly and Novartis have continued to expand their operations within Singapore after their initial investments paid off.
The government is taking a three-pronged approach:"
